Neuren Pharmaceuticals Limited
Save
1.71B
Market cap
17.03x
Current P/E
39.22x
Forward P/E

About

Health care
Sector
Biotechnology
Industry

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes.

Similar securities

Based on sector and market capitalization

Report issue